ES2531629T3 - Anticuerpos anti-MIF - Google Patents
Anticuerpos anti-MIF Download PDFInfo
- Publication number
- ES2531629T3 ES2531629T3 ES08869976.4T ES08869976T ES2531629T3 ES 2531629 T3 ES2531629 T3 ES 2531629T3 ES 08869976 T ES08869976 T ES 08869976T ES 2531629 T3 ES2531629 T3 ES 2531629T3
- Authority
- ES
- Spain
- Prior art keywords
- mif
- antibody
- once
- antigen binding
- encompasses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Anticuerpo monoclonal o parte de unión a antígeno del mismo que se une específicamente a la región que se abarca los aa 50-68 o la región que abarca los aa 86-102 de MIF humano, e inhibe la función biológica de MIF humano.
Description
5
15
25
35
45
55
65
E08869976
27-02-2015
fosfato, dextrosa, glicerol, etanol y similares, así como combinaciones de los mismos. En muchos casos, será preferible incluir agentes isotónicos, por ejemplo, azúcares, polialcoholes tales como manitol, sorbitol, o cloruro de sodio en la composición. Ejemplos adicionales de sustancias farmacéuticamente aceptables son agentes humectantes o cantidades menores de sustancias auxiliares tales como agentes humectantes o emulsionantes, conservantes o tampones, que potencian la vida útil de almacenamiento o eficacia del anticuerpo.
El anticuerpo anti-MIF de la invención y las composiciones farmacéuticas que lo comprenden pueden administrarse en combinación con uno o más de otros agentes terapéuticos, de diagnóstico o profilácticos. Los agentes terapéuticos adicionales incluyen otros agentes antineoplásicos, antitumorales, antiangiogénicos, quimioterápicos o esteroides, dependiendo de la enfermedad que va a tratarse.
Las composiciones farmacéuticas de esta invención pueden estar en una variedad de formas, por ejemplo, formas de dosificación líquidas, semisólidas y sólidas, tales como disoluciones líquidas (por ejemplo, disoluciones inyectables y para infusión), dispersiones o suspensiones, comprimidos, pastillas, polvos, liposomas y supositorios. La forma preferida depende de la aplicación terapéutica y el modo de administración previstos. Composiciones preferidas típicas están en forma de disoluciones inyectables o para infusión, tales como composiciones similares a las usadas para la inmunización pasiva de seres humanos. El modo de administración preferido es parenteral (por ejemplo, intravenoso, subcutáneo, intraperitoneal, intramuscular). En una realización preferida, el anticuerpo se administra mediante infusión o inyección intravenosa. En otra realización preferida, el anticuerpo se administra mediante inyección intramuscular o subcutánea. Tal como apreciará el experto en la técnica, la vía y/o el modo de administración variarán dependiendo de los resultados deseados.
El anticuerpo anti-MIF puede administrarse una vez, pero más preferiblemente se administra múltiples veces. Por ejemplo, el anticuerpo puede administrarse desde tres veces al día hasta una vez cada seis meses o más. La administración puede realizarse en un programa tal como de tres veces al día, dos veces al día, una vez al día, una vez cada dos días, una vez cada tres días, una vez a la semana, una vez cada dos semanas, una vez cada mes, una vez cada dos meses, una vez cada tres meses y una vez cada seis meses.
La invención también abarca el uso de un anticuerpo anti-MIF o un fragmento de unión a antígeno del mismo, en la fabricación de un medicamento para el tratamiento de enfermedades inmunológicas tales como enfermedades inflamatorias y trastornos hiperproliferativos.
La invención abarca además un anticuerpo anti-MIF o un fragmento de unión a antígeno del mismo, para su uso en el tratamiento de enfermedades inmunológicas tales como enfermedades inflamatorias y trastornos hiperproliferativos.
La invención también abarca un anticuerpo anti-MIF o un fragmento de unión a antígeno del mismo, para su uso en métodos de diagnóstico. En una realización, el anticuerpo anti-MIF o parte de unión a antígeno del mismo puede usarse para detectar MIF humano en una muestra biológica.
Los anticuerpos anti-MIF o las partes de unión a antígeno de los mismos también pueden usarse para determinar el nivel de MIF en superficie celular en un tejido o en células derivadas a partir del tejido. En algunas realizaciones, el tejido es tejido enfermo. Entonces puede usarse el tejido en un inmunoensayo para determinar, por ejemplo, niveles de MIF total, niveles de MIF en superficie celular o ubicación de MIF.
La invención se refiere además a kits que comprenden un anticuerpo anti-MIF o una parte de unión a antígeno de la invención o una composición farmacéutica que comprende un anticuerpo o una parte de este tipo. Un kit puede incluir, además del anticuerpo o la composición farmacéutica, agentes de diagnóstico o terapéuticos. Un kit también puede incluir instrucciones para su uso en un método de diagnóstico o terapéutico.
La invención se refiere además a un procedimiento para la identificación de anticuerpos anti-MIF que pueden inhibir la función biológica de MIF humano e inducir un efecto beneficioso en un modelo animal llevando a cabo las siguientes etapas:
a) seleccionar un anticuerpo que se une a MIF activo y no se une a MIF no activo,
b) someter a prueba dicho anticuerpo en ensayos in vitro, tales como ensayo de anulación de glucocorticoides (GCO) o ensayos de proliferación celular,
c) seleccionar un anticuerpo que inhibe GCO y/o la proliferación celular.
Los resultados han mostrado que un anticuerpo anti-MIF que sólo se une a MIF activo y no se une a MIF no activo e inhibe además GCO y/o la proliferación celular induce un efecto beneficioso en un modelo animal (por ejemplo, el ejemplo 6).
La presente invención se ilustrará adicionalmente mediante los siguientes ejemplos, sin ninguna limitación a los
9
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1898808P | 2008-01-04 | 2008-01-04 | |
US18988P | 2008-01-04 | ||
US9468508P | 2008-09-05 | 2008-09-05 | |
US94685P | 2008-09-05 | ||
PCT/EP2008/011146 WO2009086920A1 (en) | 2008-01-04 | 2008-12-30 | Anti mif antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2531629T3 true ES2531629T3 (es) | 2015-03-18 |
Family
ID=40535633
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES16183733T Active ES2791333T3 (es) | 2008-01-04 | 2008-12-30 | Anticuerpos anti-MIF para su uso en el tratamiento de enfermedades inflamatorias |
ES14163839.5T Active ES2623653T3 (es) | 2008-01-04 | 2008-12-30 | Anticuerpos anti-MIF |
ES08869976.4T Active ES2531629T3 (es) | 2008-01-04 | 2008-12-30 | Anticuerpos anti-MIF |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES16183733T Active ES2791333T3 (es) | 2008-01-04 | 2008-12-30 | Anticuerpos anti-MIF para su uso en el tratamiento de enfermedades inflamatorias |
ES14163839.5T Active ES2623653T3 (es) | 2008-01-04 | 2008-12-30 | Anticuerpos anti-MIF |
Country Status (23)
Country | Link |
---|---|
US (3) | US20090220521A1 (es) |
EP (4) | EP3118223B8 (es) |
JP (1) | JP5502752B2 (es) |
KR (2) | KR101654678B1 (es) |
CN (2) | CN103724430B (es) |
AU (1) | AU2008346517B2 (es) |
BR (1) | BRPI0821682A2 (es) |
CA (1) | CA2711029A1 (es) |
CY (1) | CY1117302T1 (es) |
DK (1) | DK2231707T3 (es) |
ES (3) | ES2791333T3 (es) |
HK (1) | HK1147762A1 (es) |
HR (1) | HRP20150224T1 (es) |
IL (1) | IL206715A (es) |
MX (1) | MX2010007406A (es) |
NZ (3) | NZ586600A (es) |
PL (2) | PL2231707T3 (es) |
PT (1) | PT2231707E (es) |
RS (1) | RS53906B1 (es) |
RU (2) | RU2509777C2 (es) |
SI (1) | SI2231707T1 (es) |
WO (1) | WO2009086920A1 (es) |
ZA (1) | ZA201004973B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2231707T3 (en) * | 2008-01-04 | 2015-03-02 | Baxter Int | Anti-mif antibodies |
WO2013010955A1 (en) | 2011-07-15 | 2013-01-24 | Morphosys Ag | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
WO2013050457A1 (en) | 2011-10-07 | 2013-04-11 | Baxter Healthcare S.A. | Characterization of cho-mif gene and protein, and use thereof |
WO2013050453A1 (en) | 2011-10-07 | 2013-04-11 | Baxter Healthcare S.A. | Oxmif as a diagnostic marker |
AU2013203957B9 (en) * | 2012-04-16 | 2015-10-15 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Glucocorticoids |
AU2013202693B2 (en) * | 2012-04-16 | 2015-01-22 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics |
JP2015523572A (ja) * | 2012-07-10 | 2015-08-13 | バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA | 抗mif免疫組織化学法 |
SG11201504392XA (en) * | 2012-12-07 | 2015-07-30 | Baxter Int | Anti-mif antibody cell migration assay |
AU2015206178A1 (en) * | 2014-01-03 | 2016-07-07 | Baxalta GmbH | Anti-MIF immunohistochemistry |
US10626166B2 (en) | 2014-08-22 | 2020-04-21 | Baxalta Incorporated | Detection of CHO-MIF contaminations |
EP3277718B1 (en) | 2015-03-31 | 2021-03-24 | Baxalta GmbH | Dosage regimen for anti-mif antibodies |
WO2016184886A1 (en) | 2015-05-18 | 2016-11-24 | Baxalta GmbH | Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras |
WO2018050833A1 (en) * | 2016-09-15 | 2018-03-22 | Ablynx Nv | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
CN109868311B (zh) * | 2017-12-01 | 2023-10-20 | 上海市精神卫生中心 | Mif及其预测二代抗精神病药物诱导的代谢不良反应的应用 |
JP2021526820A (ja) * | 2018-06-07 | 2021-10-11 | オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 癌治療のための抗oxMIF/抗CD3抗体 |
EP3757252B1 (en) | 2019-06-28 | 2022-03-30 | Walter Ag | A coated cutting tool |
AU2020397229A1 (en) | 2019-12-06 | 2022-06-30 | Oncoone Research & Development Gmbh | Anti-oxMIF/anti-CD3 bispecific antibody constructs |
WO2022069712A1 (en) * | 2020-10-02 | 2022-04-07 | Oncoone Research & Development Gmbh | IMPROVED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY |
WO2022167474A1 (en) | 2021-02-03 | 2022-08-11 | Oncoone Research & Development Gmbh | ANTI-oxMIF RADIOIMMUNOCONJUGATE |
CA3230723A1 (en) | 2021-09-03 | 2023-03-09 | Oncoone Research & Development Gmbh | Improved fc silenced anti-oxmif antibodies with reduced aggregation potential and reduced hydrophobicity |
WO2023133361A2 (en) * | 2022-01-10 | 2023-07-13 | Phenomic Ai | Anti-cthrc1 fusion proteins and methods of using the same |
CN114573693A (zh) * | 2022-04-25 | 2022-06-03 | 中国人民解放军陆军军医大学 | 一种听觉发育中免疫调节分子mif抗体制备方法 |
CN115814069B (zh) * | 2022-10-31 | 2023-07-21 | 四川大学华西医院 | Mif基因敲除的肿瘤细胞在制备肿瘤疫苗中的用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6645493B1 (en) | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
US6774227B1 (en) * | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
JPH0977799A (ja) * | 1995-09-13 | 1997-03-25 | Sapporo Immuno Diagnostic Lab:Kk | ヒト−マクロファージ遊走阻止因子(ヒト−mif)に対するモノクローナル抗体および該抗体を産生するハイブリドーマ |
SK287357B6 (sk) * | 1999-02-12 | 2010-08-09 | The Scripps Research Institute | Použitie antagonistu alfa v beta 3 na prípravu farmaceutickej kompozície na liečbu tumorových buniek a terapeutická kompozícia a súprava na liečenie tumoru alebo tumorových metastáz |
US20030235584A1 (en) * | 2000-02-28 | 2003-12-25 | Kloetzer William S. | Method for preparing anti-MIF antibodies |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
CN100457895C (zh) * | 2006-05-24 | 2009-02-04 | 中国科学院生物物理研究所 | 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用 |
DK2231707T3 (en) * | 2008-01-04 | 2015-03-02 | Baxter Int | Anti-mif antibodies |
-
2008
- 2008-12-30 DK DK08869976.4T patent/DK2231707T3/en active
- 2008-12-30 PL PL08869976T patent/PL2231707T3/pl unknown
- 2008-12-30 EP EP16183733.1A patent/EP3118223B8/en active Active
- 2008-12-30 EP EP08869976.4A patent/EP2231707B1/en active Active
- 2008-12-30 JP JP2010541032A patent/JP5502752B2/ja active Active
- 2008-12-30 PT PT08869976T patent/PT2231707E/pt unknown
- 2008-12-30 ES ES16183733T patent/ES2791333T3/es active Active
- 2008-12-30 US US12/346,309 patent/US20090220521A1/en not_active Abandoned
- 2008-12-30 WO PCT/EP2008/011146 patent/WO2009086920A1/en active Application Filing
- 2008-12-30 CN CN201410037650.3A patent/CN103724430B/zh active Active
- 2008-12-30 NZ NZ586600A patent/NZ586600A/en unknown
- 2008-12-30 KR KR1020107017306A patent/KR101654678B1/ko active IP Right Grant
- 2008-12-30 NZ NZ596409A patent/NZ596409A/xx unknown
- 2008-12-30 RS RS20150197A patent/RS53906B1/en unknown
- 2008-12-30 ES ES14163839.5T patent/ES2623653T3/es active Active
- 2008-12-30 ES ES08869976.4T patent/ES2531629T3/es active Active
- 2008-12-30 EP EP20120189220 patent/EP2548890A1/en not_active Withdrawn
- 2008-12-30 CN CN200880127872.7A patent/CN101983207B/zh active Active
- 2008-12-30 BR BRPI0821682-7A patent/BRPI0821682A2/pt not_active IP Right Cessation
- 2008-12-30 RU RU2010132647/10A patent/RU2509777C2/ru active
- 2008-12-30 SI SI200831400T patent/SI2231707T1/sl unknown
- 2008-12-30 EP EP14163839.5A patent/EP2754671B1/en active Active
- 2008-12-30 KR KR1020167023984A patent/KR20160105943A/ko not_active Application Discontinuation
- 2008-12-30 CA CA2711029A patent/CA2711029A1/en not_active Abandoned
- 2008-12-30 NZ NZ611117A patent/NZ611117A/en unknown
- 2008-12-30 AU AU2008346517A patent/AU2008346517B2/en active Active
- 2008-12-30 PL PL16183733T patent/PL3118223T3/pl unknown
- 2008-12-30 MX MX2010007406A patent/MX2010007406A/es active IP Right Grant
-
2010
- 2010-04-26 US US12/767,635 patent/US8668909B2/en active Active
- 2010-06-30 IL IL206715A patent/IL206715A/en active IP Right Grant
- 2010-07-14 ZA ZA2010/04973A patent/ZA201004973B/en unknown
-
2011
- 2011-02-21 HK HK11101702.4A patent/HK1147762A1/xx unknown
-
2013
- 2013-12-03 RU RU2013153592/10A patent/RU2013153592A/ru not_active Application Discontinuation
-
2014
- 2014-01-17 US US14/157,967 patent/US20150023978A1/en not_active Abandoned
-
2015
- 2015-02-26 HR HRP20150224TT patent/HRP20150224T1/hr unknown
- 2015-03-13 CY CY20151100250T patent/CY1117302T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2531629T3 (es) | Anticuerpos anti-MIF | |
Wedemeyer et al. | Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial | |
Lok et al. | Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos (t) ide-naive patients with chronic hepatitis B | |
Garcia-Pola Vallejo et al. | Anxiety and depression as risk factors for oral lichen planus | |
Lawitz et al. | Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy | |
Zhang et al. | H3 relaxin protects against myocardial injury in experimental diabetic cardiomyopathy by inhibiting myocardial apoptosis, fibrosis and inflammation | |
US20140004080A1 (en) | Use of low dose il-2 for treating autoimmune - related or inflammatory disorders | |
Li et al. | Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg‐positive chronic hepatitis B: a five‐year observational cohort study | |
US20210283105A1 (en) | Novel regimes of fxr agonists | |
EP2844291A1 (en) | Methods for treating idiopathic pulmonary fibrosis | |
Shokoples et al. | Angiotensin II-induced a steeper blood pressure elevation in IL-23 receptor-deficient mice: Role of interferon-γ-producing T cells | |
Tsoutsou et al. | Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC) | |
Belperio et al. | Pulmonary sarcoidosis: a comprehensive review: past to present | |
Wang et al. | Bosentan for treatment of pediatric idiopathic pulmonary arterial hypertension: state-of-the-art | |
Wong et al. | Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update | |
Ziemssen et al. | Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study | |
KR20160125466A (ko) | 매트릭스 메탈로프로테이나제 9에 대한 항체 및 그의 사용 방법 | |
Smith et al. | Ledipasvir–sofosbuvir for hepatitis C genotype 4 infection | |
Milara et al. | Targeting IL-11 system as a treatment of pulmonary arterial hypertension | |
Arkhipov et al. | Study of macrophages in BCG granulomas in different compartments of the mononuclear phagocyte system | |
Sohn et al. | GX-I7 (rhIL-7-hyFc, efineptakin alfa), a long-acting IL-7, safely and effectively increased peripheral CD8+ and CD4+ T cells and TILs in patients with solid tumors | |
Hernández-Oropeza et al. | Pulmonary vasoreactivity and phenotypes in pulmonary arterial hypertension associated to connective tissue diseases | |
Monastirli et al. | Classic form of eosinophilic pustular folliculitis in an immunocompetent girl: rapid and complete resolution after low-dose oral indomethacin treatment | |
Chen et al. | A Phase I, Randomized, Observer-Blinded, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers | |
Tokgözoğlu et al. | Two years of multidisciplinary diagnostic and therapeutic experience in patients with pulmonary arterial hypertension |